Muster Viktoria, Gary Thomas
Division of Vascular Medicine, Department of Internal Medicine, Medical University of Graz, Graz 8036, Austria.
Cancers (Basel). 2020 May 26;12(6):1354. doi: 10.3390/cancers12061354.
Cancer is an independent risk factor for the development of venous thromboembolism (VTE). Glioblastomas are amongst cancer types with the most thrombogenic potential and patients are at a particularly high risk of VTE with an incidence up to 20-30% per year. Currently, major efforts are underway to gain novel insights into risk factors and pathomechanisms to provide a better understanding of development of VTE in patients with primary brain tumors. Treatment of VTE requires therapeutic anticoagulation, which accordingly to recently-published guidelines should be performed using low molecular weight heparin or, in case of low bleeding risk, using a direct oral anticoagulant. However, this can be very challenging due to an increased risk of intracranial hemorrhage in this patient group. Furthermore, limited data are available on the subgroup of patients with primary brain tumors.
癌症是静脉血栓栓塞（VTE）发生的独立危险因素。胶质母细胞瘤是具有最高血栓形成潜力的癌症类型之一，患者发生VTE的风险特别高，每年的发生率高达20%-30%。目前，人们正在做出重大努力，以深入了解危险因素和发病机制，以便更好地理解原发性脑肿瘤患者VTE的发生情况。VTE的治疗需要进行抗凝治疗，根据最近发布的指南，应使用低分子量肝素进行治疗，或者在出血风险较低的情况下，使用直接口服抗凝剂。然而，由于该患者群体颅内出血风险增加，这可能极具挑战性。此外，关于原发性脑肿瘤患者亚组的数据有限。
